HRP20240215T1 - Sredstva sa visokim afinitetom za ciljani učinak na membranski antigen specifičan za prostatu za endoradioterapiju raka prostate - Google Patents
Sredstva sa visokim afinitetom za ciljani učinak na membranski antigen specifičan za prostatu za endoradioterapiju raka prostate Download PDFInfo
- Publication number
- HRP20240215T1 HRP20240215T1 HRP20240215TT HRP20240215T HRP20240215T1 HR P20240215 T1 HRP20240215 T1 HR P20240215T1 HR P20240215T T HRP20240215T T HR P20240215TT HR P20240215 T HRP20240215 T HR P20240215T HR P20240215 T1 HRP20240215 T1 HR P20240215T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- image
- compound
- cell
- tumors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662311697P | 2016-03-22 | 2016-03-22 | |
| EP21177643.0A EP3925952B1 (en) | 2016-03-22 | 2017-03-22 | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240215T1 true HRP20240215T1 (hr) | 2024-04-26 |
Family
ID=59899817
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240215TT HRP20240215T1 (hr) | 2016-03-22 | 2017-03-22 | Sredstva sa visokim afinitetom za ciljani učinak na membranski antigen specifičan za prostatu za endoradioterapiju raka prostate |
| HRP20211386TT HRP20211386T1 (hr) | 2016-03-22 | 2017-03-22 | Sredstva sa visokim afinitetom za ciljano djelovanje na membranski antigen specifičan za prostatu za endoradioterapiju raka prostate |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211386TT HRP20211386T1 (hr) | 2016-03-22 | 2017-03-22 | Sredstva sa visokim afinitetom za ciljano djelovanje na membranski antigen specifičan za prostatu za endoradioterapiju raka prostate |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US11458213B2 (enExample) |
| EP (3) | EP3433238B1 (enExample) |
| JP (3) | JP7073270B2 (enExample) |
| KR (4) | KR20220063298A (enExample) |
| CN (3) | CN120172884A (enExample) |
| AU (1) | AU2017238181B2 (enExample) |
| BR (1) | BR112018069507A2 (enExample) |
| CA (1) | CA3018709A1 (enExample) |
| CL (1) | CL2018002683A1 (enExample) |
| CY (1) | CY1124487T1 (enExample) |
| DK (2) | DK3925952T3 (enExample) |
| ES (2) | ES2877572T3 (enExample) |
| FI (1) | FI3925952T3 (enExample) |
| HR (2) | HRP20240215T1 (enExample) |
| HU (2) | HUE065327T2 (enExample) |
| LT (2) | LT3925952T (enExample) |
| MX (1) | MX384823B (enExample) |
| PH (1) | PH12018502048A1 (enExample) |
| PL (2) | PL3925952T3 (enExample) |
| PT (2) | PT3925952T (enExample) |
| RS (2) | RS62274B1 (enExample) |
| RU (2) | RU2021115958A (enExample) |
| SA (1) | SA518400103B1 (enExample) |
| SI (2) | SI3925952T1 (enExample) |
| TR (1) | TR201813644T1 (enExample) |
| WO (1) | WO2017165473A1 (enExample) |
| ZA (1) | ZA201806389B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109803973B (zh) | 2016-08-10 | 2022-05-24 | 癌靶技术有限责任公司 | 螯合psma抑制剂 |
| WO2018098390A1 (en) * | 2016-11-23 | 2018-05-31 | Cancer Targeted Technology Llc | Albumin-binding psma inhibitors |
| CN116474108A (zh) | 2016-12-14 | 2023-07-25 | 普渡研究基金会 | 成纤维细胞活化蛋白(fap)-靶向成像和治疗 |
| JP7373998B2 (ja) | 2017-05-02 | 2023-11-06 | コーネル・ユニバーシティー | 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬 |
| JP2020522506A (ja) * | 2017-05-30 | 2020-07-30 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 前立腺がんの内部放射線療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤 |
| EP4008359B1 (en) * | 2017-12-11 | 2024-09-11 | Technische Universität München | Psma ligands for imaging and endoradiotherapy |
| EP3494998A1 (en) * | 2017-12-11 | 2019-06-12 | Technische Universität München | Glycosylated psma inhibitors for imaging and endoradiotherapy |
| EP3494999A1 (en) * | 2017-12-11 | 2019-06-12 | Technische Universität München | Psma ligands for imaging and endoradiotherapy |
| MX2020006112A (es) * | 2017-12-13 | 2020-08-24 | Sciencons AS | Complejo que comprende un compuesto orientado a psma vinculado a un radionucleido de plomo o torio. |
| IL276528B2 (en) * | 2018-02-06 | 2024-11-01 | Univ Johns Hopkins | PSMA Targeted Radiohalogenated Urea-Polyaminocarboxylates For Cancer Radiotherapy |
| AU2019219057B2 (en) * | 2018-02-06 | 2022-11-24 | Universität Heidelberg | FAP inhibitor |
| MY197419A (en) * | 2018-03-30 | 2023-06-16 | Futurechem Co Ltd | Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer |
| AU2019287595B2 (en) | 2018-04-27 | 2024-10-31 | University Of Iowa Research Foundation | Compositions for chelating metals at low temperatures |
| BR112021005931A2 (pt) * | 2018-09-28 | 2021-06-29 | Universität Heidelberg | composto, complexo e composição farmacêutica |
| RU2697519C1 (ru) * | 2018-10-15 | 2019-08-15 | Общество с ограниченной ответственностью "Изварино Фарма" | Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом |
| KR102403970B1 (ko) * | 2018-12-27 | 2022-05-31 | (주)퓨쳐켐 | 카르복시산이 도입된 psma-표적 화합물 및 그의 용도 |
| EP3993837A1 (en) * | 2019-07-02 | 2022-05-11 | Advanced Accelerator Applications (Italy) Srl | Prostate specific membrane antigen (psma) ligands and uses thereof |
| RU2713151C1 (ru) * | 2019-07-02 | 2020-02-04 | Общество с ограниченной ответственностью "Изварино Фарма" | Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения |
| EP3993838A1 (en) * | 2019-07-02 | 2022-05-11 | Novartis AG | Prostate specific membrane antigen (psma) ligands and uses thereof |
| RU2730507C1 (ru) * | 2019-08-27 | 2020-08-24 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Соединение для диагностики опухолей, экспрессирующих псма, и композиция на его основе |
| IL297323A (en) | 2020-04-29 | 2022-12-01 | Novartis Ag | Methods for radiological labeling of psma-binding ligands and their kits |
| WO2022043556A1 (en) | 2020-08-31 | 2022-03-03 | Novartis Ag | Stable radiopharmaceutical composition |
| WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| US20230338587A1 (en) | 2020-08-31 | 2023-10-26 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| EP4244216A1 (en) | 2020-11-12 | 2023-09-20 | ABX Advanced Biochemical Compounds GmbH | Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks |
| EP4247798B1 (en) * | 2020-11-19 | 2025-08-27 | Novartis AG | Synthesis of prostate specific membrane antigen (psma) ligands |
| MX2021005089A (es) * | 2021-04-30 | 2022-11-01 | Instituto Nac De Investigaciones Nucleares | Radiofarmacos basados en el acido ((r)-1-((6-hidrazinilnicotinoil) d-alanil)pirrolidin-2-il)boronico (hynic-ifap) para la deteccion de la sobreexpresion de la proteina de activacion de fibrolastos. |
| KR20240022616A (ko) * | 2021-06-17 | 2024-02-20 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 복수의 킬레이트제와 생물학적 제제를 조합하기 위한 방법 및 재료 |
| KR20230050552A (ko) * | 2021-10-07 | 2023-04-17 | (주)퓨쳐켐 | 가돌리늄 화합물 및 이를 포함하는 전립선암의 진단 및 치료용 약학적 조성물 |
| JP2025506001A (ja) | 2022-02-09 | 2025-03-05 | ノバルティス アーゲー | ２２５－アクチニウム標識錯体及びビスマス封鎖剤を含む医薬組成物 |
| KR20250127126A (ko) * | 2022-12-21 | 2025-08-26 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 복수의 킬레이트제와 생물학적 제제를 조합하기 위한 방법 및 재료 |
| WO2025022285A2 (en) | 2023-07-21 | 2025-01-30 | Novartis Ag | Psma-targeting radioligand treatment regimen |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2921482B1 (en) * | 2007-06-26 | 2018-09-05 | The Johns Hopkins University | Labeled inhibitors of prostate-specific membrane antigen (psma), biological evaluation, and use as imaging agents |
| US9422234B2 (en) | 2007-11-30 | 2016-08-23 | The Johns Hopkins University | Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer |
| JP2012511024A (ja) * | 2008-12-05 | 2012-05-17 | モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド | 癌の治療及び撮像用のｃａ−ｉｘ特異性放射性医薬品 |
| CA2755965C (en) * | 2009-03-19 | 2019-04-16 | The Johns Hopkins University | Psma-targeting compounds and uses thereof |
| JP5843338B2 (ja) | 2011-08-05 | 2016-01-13 | モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド | 放射標識された前立腺特異的膜抗原阻害剤 |
| US9371360B2 (en) * | 2011-11-30 | 2016-06-21 | The Johns Hopkins University | Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (PSMA) and uses thereof |
| ES2648096T3 (es) * | 2013-01-14 | 2017-12-28 | Molecular Insight Pharmaceuticals, Inc. | Radiofármacos a base de triazina y agentes de radioformación de imágenes |
| EP2862857A1 (en) * | 2013-10-18 | 2015-04-22 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| SG11201602249RA (en) * | 2013-10-18 | 2016-05-30 | Deutsches Krebsforsch | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| CN106660943B (zh) * | 2014-05-06 | 2020-03-17 | 约翰霍普金斯大学 | 用于psma靶向的成像和放射疗法的金属/放射性金属标记的psma抑制物 |
| ES2912753T3 (es) | 2014-08-24 | 2022-05-27 | Max Planck Gesellschaft Zur Foerderung Der Wss | Método para la producción de ésteres activos marcados con 18F y su aplicación ejemplificada por la preparación de un marcador de PET específico de PSMA |
| WO2016065435A2 (en) * | 2014-10-30 | 2016-05-06 | Katholieke Universiteit Leuven | Methods for low temperature fluorine-18 radiolabeling of biomolecules |
| US11520472B2 (en) * | 2015-09-24 | 2022-12-06 | Mitutoyo Corporation | Inspection program editing environment including integrated alignment program planning and editing features |
| US10688200B2 (en) | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
-
2017
- 2017-03-22 KR KR1020227015010A patent/KR20220063298A/ko not_active Ceased
- 2017-03-22 HR HRP20240215TT patent/HRP20240215T1/hr unknown
- 2017-03-22 EP EP17771028.2A patent/EP3433238B1/en active Active
- 2017-03-22 LT LTEP21177643.0T patent/LT3925952T/lt unknown
- 2017-03-22 DK DK21177643.0T patent/DK3925952T3/da active
- 2017-03-22 US US16/087,395 patent/US11458213B2/en active Active
- 2017-03-22 WO PCT/US2017/023508 patent/WO2017165473A1/en not_active Ceased
- 2017-03-22 EP EP24153551.7A patent/EP4385981A1/en active Pending
- 2017-03-22 RU RU2021115958A patent/RU2021115958A/ru unknown
- 2017-03-22 EP EP21177643.0A patent/EP3925952B1/en active Active
- 2017-03-22 RS RS20211071A patent/RS62274B1/sr unknown
- 2017-03-22 CN CN202510305793.6A patent/CN120172884A/zh active Pending
- 2017-03-22 MX MX2018011519A patent/MX384823B/es unknown
- 2017-03-22 PT PT211776430T patent/PT3925952T/pt unknown
- 2017-03-22 AU AU2017238181A patent/AU2017238181B2/en active Active
- 2017-03-22 KR KR1020187030310A patent/KR102396307B1/ko active Active
- 2017-03-22 BR BR112018069507A patent/BR112018069507A2/pt unknown
- 2017-03-22 ES ES17771028T patent/ES2877572T3/es active Active
- 2017-03-22 DK DK17771028.2T patent/DK3433238T3/da active
- 2017-03-22 PT PT177710282T patent/PT3433238T/pt unknown
- 2017-03-22 FI FIEP21177643.0T patent/FI3925952T3/fi active
- 2017-03-22 LT LTEPPCT/US2017/023508T patent/LT3433238T/lt unknown
- 2017-03-22 CN CN201780031580.2A patent/CN109311827B/zh active Active
- 2017-03-22 RS RS20240205A patent/RS65188B1/sr unknown
- 2017-03-22 PL PL21177643.0T patent/PL3925952T3/pl unknown
- 2017-03-22 JP JP2018549808A patent/JP7073270B2/ja active Active
- 2017-03-22 CN CN202210306552.XA patent/CN114716387B/zh active Active
- 2017-03-22 SI SI201731477T patent/SI3925952T1/sl unknown
- 2017-03-22 RU RU2018133693A patent/RU2749399C2/ru active
- 2017-03-22 HU HUE21177643A patent/HUE065327T2/hu unknown
- 2017-03-22 CA CA3018709A patent/CA3018709A1/en active Pending
- 2017-03-22 SI SI201730908T patent/SI3433238T1/sl unknown
- 2017-03-22 PL PL17771028T patent/PL3433238T3/pl unknown
- 2017-03-22 KR KR1020237034341A patent/KR20230147751A/ko not_active Ceased
- 2017-03-22 HR HRP20211386TT patent/HRP20211386T1/hr unknown
- 2017-03-22 TR TR2018/13644A patent/TR201813644T1/tr unknown
- 2017-03-22 KR KR1020257012794A patent/KR20250057132A/ko active Pending
- 2017-03-22 ES ES21177643T patent/ES2972148T3/es active Active
- 2017-03-22 HU HUE17771028A patent/HUE055607T2/hu unknown
-
2018
- 2018-09-21 CL CL2018002683A patent/CL2018002683A1/es unknown
- 2018-09-24 PH PH12018502048A patent/PH12018502048A1/en unknown
- 2018-09-25 ZA ZA2018/06389A patent/ZA201806389B/en unknown
- 2018-09-25 SA SA518400103A patent/SA518400103B1/ar unknown
-
2021
- 2021-09-13 CY CY20211100803T patent/CY1124487T1/el unknown
-
2022
- 2022-05-11 JP JP2022077992A patent/JP2022116028A/ja active Pending
- 2022-08-22 US US17/892,203 patent/US20230015736A1/en not_active Abandoned
-
2024
- 2024-01-11 JP JP2024002743A patent/JP2024050608A/ja active Pending
- 2024-12-13 US US18/979,841 patent/US20250195700A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240215T1 (hr) | Sredstva sa visokim afinitetom za ciljani učinak na membranski antigen specifičan za prostatu za endoradioterapiju raka prostate | |
| JP2019519467A5 (enExample) | ||
| AU2019365377B2 (en) | Marking precursor with squaric acid coupling | |
| AU2019356168B2 (en) | Imaging agents | |
| HRP20220742T1 (hr) | Sredstva koja se vežu na psma i njihova upotreba | |
| IL318462A (en) | Fap-alpha specific tumor diagnostic imaging agent | |
| JP2025118743A5 (enExample) | ||
| IL313103B1 (en) | Psma ligands for imaging and endoradiotherapy | |
| BR112014027190A2 (pt) | pirrolobenzodiazepinas | |
| IL266563B (en) | Heterocyclic compounds useful as pdk1 inhibitors | |
| HRP20191620T1 (hr) | Grpr-antagonisti za otkrivanje, dijagnostiku i liječenje grpr-pozitivnog raka | |
| AU2016375192B2 (en) | Macrocyclic ligands with picolinate group(s), complexes thereof and also medical uses thereof | |
| US20230136073A1 (en) | Novel nitrogen-containing compound or salt thereof, or metal complex thereof | |
| DK2536691T3 (en) | BIFUNCTIONAL CHELATING AGENT | |
| NZ786380B2 (en) | Prostate-Specific Membrane Antigen Targeted High-Affinity Agents For Endoradiotherapy Of Prostate Cancer | |
| JPWO2023057457A5 (enExample) | ||
| Fu et al. | Synthesis and biological evaluation of 18F-labled 2-phenylindole derivatives as PET imaging probes for β-amyloid plaques | |
| JP2008537958A5 (enExample) | ||
| CN101928327A (zh) | 用于铼和锝的三羰基络合物的双功能三齿的含吡唑基配体 | |
| KR20240072200A (ko) | 18f-표지된 실릴-플루오라이드 화합물의 제조 방법 | |
| HK40063347A (en) | Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof | |
| JPWO2023283627A5 (enExample) | ||
| HK40097471A (en) | Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof | |
| NZ763033B2 (en) | Psma ligands for imaging and endoradiotherapy | |
| NZ759832A (en) | Pharmacokinetic enhancements of bifunctional chelates and uses thereof |